CTCBIO Inc (060590) - Total Assets
Based on the latest financial reports, CTCBIO Inc (060590) holds total assets worth ₩149.18 Billion KRW (≈ $101.10 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore CTCBIO Inc (060590) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
CTCBIO Inc - Total Assets Trend (2011–2024)
This chart illustrates how CTCBIO Inc's total assets have evolved over time, based on quarterly financial data. See CTCBIO Inc net assets for net asset value and shareholders' equity analysis.
CTCBIO Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
CTCBIO Inc's total assets of ₩149.18 Billion consist of 47.9% current assets and 52.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩370.00 | 12.5% |
| Accounts Receivable | ₩20.09 Billion | 13.1% |
| Inventory | ₩30.69 Billion | 20.0% |
| Property, Plant & Equipment | ₩60.89 Billion | 39.6% |
| Intangible Assets | ₩9.97 Billion | 6.5% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how CTCBIO Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 060590 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CTCBIO Inc's current assets represent 47.9% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 12.5% of total assets in 2024, up from 4.7% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 1.0% in 2011.
- Asset Diversification: The largest asset category is property, plant & equipment at 39.6% of total assets.
CTCBIO Inc Competitors by Total Assets
Key competitors of CTCBIO Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
CTCBIO Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.16 | 1.08 | 1.20 |
| Quick Ratio | 0.70 | 0.61 | 0.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩10.12 Billion | ₩5.69 Billion | ₩12.49 Billion |
CTCBIO Inc - Advanced Valuation Insights
This section examines the relationship between CTCBIO Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.40 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -7.3% |
| Total Assets | ₩153.69 Billion |
| Market Capitalization | $47.31 Million USD |
Valuation Analysis
Below Book Valuation: The market values CTCBIO Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: CTCBIO Inc's assets decreased by 7.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for CTCBIO Inc (2011–2024)
The table below shows the annual total assets of CTCBIO Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩153.69 Billion ≈ $104.15 Million |
-7.34% |
| 2023-12-31 | ₩165.86 Billion ≈ $112.40 Million |
-11.73% |
| 2022-12-31 | ₩187.90 Billion ≈ $127.34 Million |
+11.69% |
| 2021-12-31 | ₩168.23 Billion ≈ $114.00 Million |
-5.05% |
| 2020-12-31 | ₩177.17 Billion ≈ $120.07 Million |
-5.00% |
| 2019-12-31 | ₩186.50 Billion ≈ $126.39 Million |
-2.71% |
| 2018-12-31 | ₩191.69 Billion ≈ $129.90 Million |
-0.06% |
| 2017-12-31 | ₩191.80 Billion ≈ $129.98 Million |
+1.66% |
| 2016-12-31 | ₩188.68 Billion ≈ $127.86 Million |
-2.55% |
| 2015-12-31 | ₩193.61 Billion ≈ $131.21 Million |
+19.42% |
| 2014-12-31 | ₩162.12 Billion ≈ $109.87 Million |
+7.74% |
| 2013-12-31 | ₩150.48 Billion ≈ $101.98 Million |
+20.03% |
| 2012-12-31 | ₩125.36 Billion ≈ $84.96 Million |
+34.32% |
| 2011-12-31 | ₩93.33 Billion ≈ $63.25 Million |
-- |
About CTCBIO Inc
CTCBIO Inc. provides various pharmaceutical products in South Korea and internationally. The company offers animal and human pharmaceuticals; feed additives and ingredients; and functional food products. It also provides cardiovascular, gastrointestinal, osteoporosis, antibiotic, smoking cessation, antifungal and antiviral, antiepileptic, allergic rhinitis, dermatology and genito-urinory, allergi… Read more